**Pharmaceutical Giants Continue to Downplay Dangerous Side Effects of Popular Drugs**

Written By Brady Wirick

The US Food and Drug Administration has recently been compelled to update the label of the diabetes medication, Ozempic, to address increasing reports of blocked intestines in individuals administered the drug.

Ozempic, along with its counterpart, Wegovy, which is advertised for weight loss, have surged in use among the masses. These drugs contain semaglutide, which belongs to the GLP-1 agonists group of drugs. Their mechanism is based on imitating a natural body hormone, which decelerates the movement of food through the stomach, creating a prolonged sensation of fullness.

However, the prominent drug company, Novo Nordisk, which is responsible for producing Ozempic and its similar counterpart, Wegovy, seems to be minimizing the concerns. Responding to the escalating apprehensions, the company provided a rather generic statement to CNN, emphasizing patient safety and their collaboration with the FDA to keep an eye on the “safety profile” of their drugs.

“Novo Nordisk stands firmly behind the safety and efficacy of Ozempic® and all our products when taken in line with the product description and the approved uses,” the firm articulated.

Recent modifications to the labels of Wegovy and another diabetes medication named Mounjaro reveal acknowledged reports of ileus, a term for intestinal blockage. Ozempic’s label has received similar adjustments.

In an apparent attempt to downplay the severity and frequency of these side effects, the updated label ambiguously states, “Because these reactions are reported voluntarily from a population of uncertain size, it’s challenging to provide a dependable estimate of their occurrence or ascertain a direct link to drug use.”

An alarming number of users of Ozempic and Wegovy have also narrated incidents of gastroparesis, or stomach paralysis. While such cases are deemed to be rare by some specialists, it’s questionable if these are directly attributed to the drugs. Novo Nordisk, seemingly brushing aside such grave claims, responded by stating the extensive research and usage history of GLP-1 agonists.

Trying to deflect concerns, Novo commented, “Gastrointestinal (GI) events are familiar side effects of the GLP-1 class. For semaglutide, the bulk of GI side effects are minor to moderate in intensity and transient. GLP-1s typically result in prolonged gastric emptying, which is clearly mentioned on each of our GLP-1 RA drug labels. Symptoms linked with delayed gastric emptying, such as nausea and vomiting, are cataloged as side effects.”

However, these reassurances have not pacified everyone. A Louisiana resident has taken legal action against both Novo Nordisk and Eli Lilly. She alleges that the “intense gastrointestinal events” she experienced after using Ozempic and Mounjaro culminated in grievous harm.

Other articles have reported serious gastrointestinal paralysis or blocking in 1% of cases. The drug companies claim that this is a minimal risk compared to the risks associated with obesity. I am sure that their stance would change if their loved ones were part of that 1


Submit a Comment

Your email address will not be published. Required fields are marked *